All In Biotech

Drug Trial Radar · NCT07924059

Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia

A Phase 3, Randomized, Double-blind, Active Controlled, Multi-center Trial Investigating the Efficacy and Safety of Dual Therapy With Once-weekly Navepegritide and Once-weekly Lonapegsomatropin Compared to Navepegritide Monotherapy and Lonapegsomatropin Monotherapy in Children and Adolescents With Achondroplasia

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Sep 2028

Study completion Sep 2029

Sponsor

Lead sponsor
Ascendis Pharma A/SIndustry
Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pivotal trial is being conducted to evaluate the efficacy, safety and tolerability of dual therapy with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 17 years.

Conditions

  • Achondroplasia

Interventions

  • Dual therapy with navepegritide and lonapegsomatropinDrug

    Administered weekly as two separate SC injections. Treatment duration of up to 104 weeks

  • Dual therapy with navepegritide and placebo for lonapegsomatropinDrug

    Administered as two separate SC injections. Treatment duration of up to 52 weeks of navepegritide and placebo for lonapegsomatropin followed by 52 weeks of navepegritide and lonapegsomatropin.

  • Dual therapy with lonapegsomatropin and placebo for navepegritideDrug

    Administered as two separate SC injections. Treatment duration of up to 52 weeks of lonapegsomatropin and placebo for navepegritide followed by 52 weeks of navepegritide and lonapegsomatropin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Growth Velocity (AGV)Time frame: 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.